Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Intro to finding retirement index funds with the lowest expense ratios and tips for evaluating ongoing costs.
27,234 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Bitcoin rebounded from a sub-$62,000 dip while Pi Network’s PI slumped to new lows. The split move underscores ongoin...
Jim Cramer challenges a fresh downgrade on Apple, arguing the stock’s AI ambitions and a possible 2027 supercycle jus...
Lucid Group bucked volatility in the electric-vehicle space, rising for a third consecutive session and surpassing ke...
The World Liberty Forum opens with WLFI up 18%, highlighting renewed investor interest in crypto assets as policymake...
Investors are watching Viking Therapeutics as its obesity drug candidate approaches key milestones. This article brea...
As XPEL gears up for 2025 earnings insights, investors need a clear view of growth drivers, margin discipline, and po...
A growing cohort of workers is quietly stacking multiple full-time roles, pushing total earnings into six figures and...
Bitcoin moved sharply amid Middle East tensions and a U.S. strike on Iran, slipping before a quick rebound. Analysts ...
B&G Foods is in the spotlight as its stock roars higher. This article explains the mix of quarterly results, strategi...
As 2026 begins, homebuilders contend with thinner margins, stubborn demand, and growing war-risk headwinds, forcing l...
Bitcoin slipped below $67,000 on Sunday, testing a key level as Pi Network's PI tumbled after a sharp rally. Traders ...